点击 最 下方 关注《材料汇》 ， 点击"❤"和" "并分享 添加 小编微信 ，寻 志同道合 的你 在科技浪潮奔涌向前的当下，新材料宛如璀璨星辰，照亮了各行业创新发展的征途。从电子信息的微观 世界，到新能源的宏大布局；从生物医用的生命呵护，到航空航天的探索前沿，新材料的每一次突破， 都在重塑我们的生活与产业版图。今天，就让我们一同深入这场"100大最具潜力新材料评选"，领略那 些正改写未来的神奇材料。 延伸阅读： "十五五"新材料产业发展规划 | 导体 | 材料 | 舞蹈 演 e V | 光谱胸应范围mm | 迁移率cm2/ (V·s) | | --- | --- | --- | --- | --- | | | 锡化钢 (InSb) | 0.16 | 1000-7000 | 78,000 (室温) 1,000,000 (77K) | | 第四代:超窄禁带 | 销(Ge) | 0.66 | 550~1800 | 3900 (室温) | | | 锯化窗(GaSb) | 0.725 | 300-4300 (可调至14000) | 2500~3000 (室温) | | 第一代:元素半导体 | 硅(Si) | 1.12 ...

汇涵科技 成立于2005年，总部位于苏州，是一家融合科技、医疗与消费属性的创新型企业，专注于生物医用 材料的研发与产业化。公司旗下有高端敷料、一次性手术器械、生物医用材料及日用消费品四大板块。公司以 临床需求为导向，通过自主核心技术推动医疗产品创新，为手术管理、创面修复及组织再生提供高效解决方 案。 汇涵科技依托 胶体银技术、水凝胶技术、细菌纤维素技术、生物3D技术及MT技术 五大核心平台，为临床医 疗提供高效、安全的解决方案。 公司产品涵盖止血类、手术密封类、防黏连类、软组织管理类等全系列产品，已取得含两个三类医疗器械在内 的 50多张医疗器械注册 。此外，公司还注册了如 细菌纤维素人工血管、细菌纤维素饮品等 新产品，推动创 新材料在临床医疗与大健康领域的应用。 细菌纤维素技术 北京和上海活动报名： 第三届全球手术机器人大会 2025医疗器械研发创新论坛 近日， 苏州汇涵医用科技发展有限公司 （以下简称"汇涵科技"）宣布完成 B轮融资 ，此次融资由江苏润淮 产业发展基金独家投资，资金将主要用于汇涵科技旗下生物医用材料板块的产能扩建、自动化升级及研发创 新。 # 关于汇涵科技 融资历程 思宇年度活动回顾： 首 ...

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

Group 1 - The stock price of Youyan New Materials closed at 18.77 yuan on July 31, 2025, down 1.47% from the previous trading day, with a trading volume of 742 million yuan [1] - Youyan New Materials is primarily engaged in the research and production of rare earth materials, optoelectronic materials, and biomedical materials, covering sectors such as new energy and new materials [1] - The company announced that its subsidiary, Youyan Rare Earth, has completed the transfer of lithium sulfide business-related assets to Shanghai Xiba Technology Co., Ltd., with a total transaction value of approximately 110 million yuan, involving proprietary technology, patents, and equipment [1] Group 2 - On July 31, Youyan New Materials experienced a net outflow of main funds amounting to 102 million yuan [2]

Core Viewpoint - The article highlights the significance of innovative medical devices in the treatment of cervical cancer, particularly focusing on the introduction of the absorbable protective hydrogel, Respacio®, developed by Shanghai Ruining Biotechnology Co., Ltd. This product aims to reduce radiation damage during cancer treatment, addressing a critical need in the healthcare sector [1][5][20]. R&D Background - Cervical cancer is a major public health issue for women globally, ranking as the fourth most common cancer among women, with approximately 604,000 new cases and 342,000 deaths reported in 2020 by WHO [3]. - In China, cervical cancer is the second most common malignant tumor in the female reproductive system, with around 110,000 new cases and 34,000 deaths annually as of 2022 [3]. - A significant percentage (70%) of cervical cancer patients are diagnosed at advanced stages (FIGO II-III), complicating treatment and increasing risks of side effects [3]. Product Introduction - Respacio® is the first domestic absorbable protective hydrogel specifically designed for tumor radiotherapy, particularly for cervical and prostate cancer treatments [5][20]. - The hydrogel forms a physical barrier between the tumor and surrounding healthy tissues, significantly reducing radiation exposure to healthy organs and enhancing treatment safety and efficacy [7][10]. Clinical Research and Data - A prospective Phase I clinical trial conducted by the radiotherapy team at Peking Union Medical College Hospital demonstrated the safety and effectiveness of Respacio® in cervical cancer patients, with no severe acute toxic reactions observed [16]. - The trial involved eight patients, all of whom did not experience grade 3 or higher acute toxicity reactions, and no late rectal toxicity was reported [16]. - The hydrogel showed a reduction in volume over a period of 24 to 36 weeks post-injection, indicating its effective absorption and degradation [16]. Competitive Landscape - Currently, there are no mature absorbable hydrogel products in the domestic radiotherapy protection market, making Respacio® the first to enter the registered clinical trial phase [20]. - Internationally, similar products include SpaceOAR® Hydrogel, which has a significant market presence with annual sales exceeding $200 million, demonstrating its effectiveness in reducing rectal radiation dose by approximately 70% [21][20]. Company Overview - Shanghai Ruining Biotechnology Co., Ltd., established in 2018, focuses on the research and industrialization of high-end biomedical materials [24]. - The company has developed a leading medical hydrogel technology platform and has a rich pipeline of innovative medical devices, including tumor embolization hydrogels and intrauterine adhesion prevention hydrogels [24].

Core Viewpoint - The successful registration of medical-grade PHA microsphere materials by Zhuhai Maide Biological Technology Co., Ltd. marks a significant advancement in the standardization and regulation of domestic biomedical materials, providing new momentum for the development and industrialization of downstream medical device products [1][5]. Group 1: Main Document Registration - The main document registration system aims to streamline the registration process for medical devices by standardizing the quality data management of key raw materials [2]. - The registration of Maide Biological's medical-grade PHA microspheres will serve as a standardized raw material for Class III absorbable medical devices and drug delivery applications [2]. - Key benefits of the registration include lowering registration barriers, shortening review cycles, and ensuring controllable quality through comprehensive data on the physicochemical properties and biocompatibility of PHA microspheres [2]. Group 2: PHA as a Future Star in Biomedical Materials - Polyhydroxyalkanoates (PHA) are natural polymers synthesized by microorganisms, known for their biodegradability, biocompatibility, and customizable mechanical properties [3]. - PHA degrades into carbon dioxide and water in the body, promoting ATP production and aiding tissue repair, making it an ideal choice for implantable medical devices [3]. - Maide Biological has established a comprehensive technological barrier covering the purification, large-scale production, and end-use applications of medical-grade PHA [3]. Group 3: Core Patent and Production Capacity - The company has developed proprietary purification processes for medical-grade PHA, addressing batch stability issues and has applied for over 50 domestic and international patents [4]. - The production capacity has been upgraded with a thousand-ton production line in Zhanjiang, ensuring a stable supply of industrial-grade PHA and solidifying the supply chain for medical-grade materials [4]. Group 4: Industry Impact - The completion of the main document registration provides a high-standard raw material solution for medical device companies, promoting the independent development of high-end medical materials in China [5]. - Maide Biological aims to break the overseas technology monopoly through innovation, with the large-scale application of PHA microspheres expected to foster a new wave of domestic high-end medical devices in fields such as tumor intervention and aesthetic repair [5].

Group 1: Investment and Financing Activities - Baiyiyuan Biotechnology received several million RMB in financing from Kangzhe Pharmaceutical, aimed at new product development, market expansion, and production line upgrades [2] - Shanghai Natu Intelligent Technology completed 10 million RMB in angel round financing to develop an intelligent perception cloud platform [2] - SAIC Group's mobility brand, Xiangdao Travel, announced over 1.3 billion RMB in Series C financing, marking the largest single financing in the domestic travel industry in three years [3] - Shandong Future Robotics secured several hundred million RMB in strategic investment from PetroChina Kunlun Capital to expand production capacity and optimize operations [3] - Fanlian Information raised funds to focus on distributed storage product development and sales system upgrades [4] - Zhitong Technology completed over 100 million RMB in Series B financing to build an intelligent product manufacturing center [5] - Chuan Yuan Technology announced several million RMB in Series A financing to enhance product iteration and global brand development [5] - Xingkeyuan completed several million RMB in angel plus round financing to develop next-generation products [7] - Cloud Saint Intelligent completed 500 million RMB in Series D financing to support new product development and automated manufacturing strategies [8] - White Rhino secured 200 million RMB in Series B financing to enhance product development and supply chain optimization [8] Group 2: Company Profiles and Market Focus - Baiyiyuan Biotechnology specializes in developing and producing new biomedical materials for tissue repair and regenerative medicine [2] - Shanghai Natu Intelligent Technology focuses on intelligent perception cloud platforms, collaborating with multiple robotics manufacturers [2] - Xiangdao Travel is an internet-based ride-hailing service platform established by SAIC Group [3] - Shandong Future Robotics is a high-tech company focusing on deep-sea operation equipment and has achieved full domestic production [3] - Fanlian Information operates in the trillion-level intelligent computing center market, offering a technology ecosystem centered around high-performance distributed file systems [4] - Zhitong Technology, founded by FAW Liberation, focuses on autonomous driving technology and integrated solutions for various scenarios [5] - Chuan Yuan Technology specializes in battery lifecycle detection technology and has established a global service network [6] - Xingkeyuan is focused on the production and research of silicon-carbon anodes for lithium batteries [7] - Cloud Saint Intelligent integrates low-altitude technology and AI to promote the development of the low-altitude economy [8] - White Rhino is an L4-level autonomous driving company focusing on urban unmanned delivery [8]

Core Viewpoints - The segmented fields show differentiated growth: semiconductor materials grow at 50%, new energy materials at 52%, and biomedical materials at 87%, while traditional structural materials maintain a stable growth of 8-10% [2] - Emerging fields are rapidly rising: AI servers with high-frequency materials grow at 60%, new energy vehicles with MLCC at 100%, foldable screens with UTG glass at 30%, and hydrogen energy with a 60% localization rate for proton exchange membranes [2] - The industrial chain is changing: semiconductor materials are developed in a bundled manner with "wafer factories + material factories," while new energy materials involve a three-in-one integration of car manufacturers, battery factories, and material suppliers [2] Market Analysis - The Chinese innovative materials market has formed a diversified tiered structure, reaching a total scale of 6 trillion yuan in 2024, with a forecast to exceed 10 trillion yuan in 2025. The segmented fields show differentiated growth: semiconductor materials (50% growth), new energy materials (52%), and biomedical materials (87%) constitute three major growth poles, while traditional structural materials grow steadily at 8-10% [10][11] - The application field is being restructured, with traditional applications (aerospace, automotive manufacturing) dropping from 65% in 2019 to 48% in 2023, while emerging fields like AI servers (CCL usage growth of 60%), new energy vehicles (MLCC demand growth of 100%), and foldable screens (UTG glass demand growth of 30%) are rapidly rising [10] Competitive Landscape and Industrial Chain Evolution - The industry concentration is accelerating, showing a dual-track pattern of "national teams leading + private specialization." China National Building Material Group, as a representative of "national materials," has achieved breakthroughs in carbon fiber and silicon nitride ceramics, with R&D investment exceeding 10 billion yuan in 2023 [12] - The collaborative model in the industrial chain is innovating significantly. In the semiconductor materials field, a "wafer factory + material factory" bundled development model has formed, while new energy materials show a three-in-one R&D model involving car manufacturers, battery factories, and material suppliers [12] Future Market Space - The innovative materials market in China is expected to reach 10 trillion yuan by 2025 and exceed 30 trillion yuan by 2030, maintaining a CAGR of 18%. The growth engines come from deepening domestic substitution, technological iteration dividends, and the expansion of emerging applications [19] - Key areas to focus on include high-end photoresists, aerospace engine materials, solid-state batteries, high-temperature superconducting materials, perovskite photovoltaic materials, high-frequency materials, MLCC, UTG glass, silicon-carbon anodes, AI + new materials, and biodegradable materials [10][19] Policy Environment and Institutional Innovation - The national strategic layout provides strong support, with the Ministry of Industry and Information Technology clarifying key development directions for frontier materials, and local governments increasing support, such as Guangdong Province establishing a 10 billion yuan new materials industry fund [15] - The policy combination has shown significant effects, with the first application insurance compensation mechanism covering 80% of key materials, reducing R&D risks for enterprises by 30% [15] Technological Innovation and Industry Upgrade - The materials genome engineering is revolutionizing the R&D model, significantly shortening the development cycle of new materials [16] - Breakthroughs in production processes are reshaping cost curves, with significant reductions in unit costs and improvements in yield rates for various materials [16] Investment Strategy Recommendations - Focus on three major tracks: high-end semiconductor materials, new energy materials, and biomedical materials. Risk control should pay attention to technological route risks and the competitive landscape of leading enterprises [25][26] - The certainty of domestic substitution is high, with significant opportunities in solid-state electrolytes and superconducting materials [26]

以医美再生材料为切入点拓展至高端再生材料、仿生材料等领域。 凯乘资本表 示： " 创新生物医用材料拥有独特的组织相容性及生物功能性，具备极强的市场潜力， 是我们的重点关注方向之一。美柏生物作为该赛道的杰出代表企业，凭借其创新的 ECM 平台技术， 在消费医疗、再生医学领域均展现了强大的创新能力与商业化潜力。我们相信在肖博和各位股东的共 同努力下，美柏生物必将在生物医用材料领域持续深耕，不断拓展业务版图，为更多患者及用户带来 福祉。 " 本文由公众号IPO早知道（ID：ipozaozhidao）原创撰写，如需转载请联系C叔↓↓↓ 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据 IPO 早知道消息， 近日， 北京美柏医药生物技术发展有限公司（下称 " 美柏生物 " ） 完成数千 万元 A + + 轮融资，由可孚医疗（ 301087.SZ ）领投，中关村科技租赁（ 1601.HK ）提供中长期 资金支持，凯乘资本担任独家财务顾问。 本轮融资募集资金将主要用于进一步推进公司人源细胞外 基质（ ECM ）再生材料系列产品的研发及产业化建设，同时加速推进基于人源 ECM 再生材料的三 类医疗 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 上海昊海生物科技股份有限公司 2024 年年度报告摘要 公司代码：688366 公司简称：昊海生科 上海昊海生物科技股份有限公司 2024 年年度报告摘要 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2024年年度報告摘要》，僅供 ...